Shares of Revance Therapeutics Inc. (RVNC), which were trading around $37 at its peak in 2014, have significantly declined in value and trade around $7.
The company's flagship product is Daxxify, a neuromodulator, which was approved by the FDA for frown line treatment in September 2022, and for the treatment of cervical dystonia last August.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com